


Condition Report - ASTHMA

Drugs for ASTHMA with the most Adverse Events Reported

Drugs with the most Adverse Events Reported
 (# of Reports)



DRUGS	# OF PATIENTS (01/01/2004 TO 06/30/2012)		DEATH		LIFE THREATENING		HOSPITALIZATIONS	
	Primary	All	Primary	All	Primary	All	Primary	All
Advair	8,499 (23%)	13,817 (37%)	297 (22%)	473 (35%)	168 (9%)	474 (25%)	853 (10%)	2,545 (30%)
Xolair	4,635 (12%)	4,784 (13%)	193 (14%)	210 (16%)	266 (14%)	284 (15%)	1,373 (16%)	1,423 (17%)
Singulair	3,112 (8%)	9,343 (25%)	104 (8%)	294 (22%)	351 (18%)	600 (31%)	973 (11%)	2,538 (30%)
Symbicort	1,945 (5%)	3,393 (9%)	35 (3%)	98 (7%)	51 (3%)	149 (8%)	338 (4%)	884 (10%)
Ventolin	1,740 (5%)	11,893 (32%)	52 (4%)	432 (32%)	117 (6%)	557 (29%)	307 (4%)	2,931 (34%)
Flovent	1,506 (4%)	3,407 (9%)	12 (1%)	102 (8%)	26 (1%)	129 (7%)	150 (2%)	715 (8%)
Pulmicort	1,383 (4%)	2,808 (7%)	9 (1%)	88 (7%)	24 (1%)	116 (6%)	135 (2%)	619 (7%)
Spiriva	1,367 (4%)	2,678 (7%)	21 (2%)	104 (8%)	21 (1%)	86 (4%)	132 (2%)	602 (7%)
Humira	1,036 (3%)	1,076 (3%)	12 (1%)	13 (1%)	6 (0%)	6 (0%)	198 (2%)	213 (2%)
Serevent	906 (2%)	2,045 (5%)	33 (2%)	120 (9%)	15 (1%)	67 (3%)	66 (1%)	421 (5%)

Highcharts.com

[More](#) [Download CSV File](#)

Most Recent FDA Reports/Patient Reviews (Primary Suspect) 

REPORT DATE	DRUG NAME	REPORT TYPE	USER RATING	ADVERSE EVENTS	OUTCOME
06/29/2012	Cimzia	FDA	N/A	Chest Pain	Hospitalization - Initial or Prolonged
06/29/2012	Ventolin	FDA	N/A	Drug Ineffective Dyspnoea (Shortness Of Breath) Product Quality Issue	Unknown
06/29/2012	Ventolin	FDA	N/A	Drug Ineffective Product Quality Issue	Unknown
06/29/2012	Ventolin	FDA	N/A	Drug Screen Positive	Unknown
06/29/2012	Mulhaq	FDA	N/A	Drug Ineffective Gait Disturbance (Deviation From Normal Walking) Infarction	Other
06/29/2012	Foradil	FDA	N/A	Biopsy Skin Abnormal Blood Immunoglobulin G Decreased Blood Immunoglobulin M Decreased Dermatitis Bullous	Hospitalization - Initial or Prolonged
06/29/2012	Xolair	FDA	N/A	Ear Infection Foetal Distress Syndrome Maternal Exposure Timing Unspecified	Hospitalization - Initial or Prolonged
06/29/2012	Xeloda	FDA	N/A	Hyponatremia (Reduced Sodium In Plasma)	Death
06/29/2012	Lyrica	FDA	N/A	Abdominal Sepsis Back Pain Cardiac Disorder Fall	Hospitalization - Initial or Prolonged
06/29/2012	Xolair	FDA	N/A	Hypersensitivity Rhinorrhoea (Runny Nose) Seasonal Allergy Sneezing	Other

[More](#)

Using Saved Content

Copyright © 2013 Adverse Events, Inc. All rights reserved.
[About Us](#) | [Contact](#) | [Privacy Policy](#) | [Terms of Use](#)



Find us on Google+

[Show All](#)

[Show All](#)